Spring Bank to Host Conference Call to Discuss Fourth Quarter and Fiscal Year 2017 Results on Wednesday, February 21

Conference Call to be Held at 8:30am Eastern Time

HOPKINTON, Mass., Feb. 12, 2018 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq:SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases and certain cancers, today announced that it will host a conference call to discuss its results for the fourth quarter and fiscal year ended December 31, 2017 and its 2018 development outlook at 8:30am Eastern Time on Wednesday, February 21, 2018.

Conference Call Details
Date: Wednesday, February 21, 2018
Time: 8:30am Eastern Time
US: 800-289-0517
International: 323-794-2423
Conference ID: 5789868
Webcast: http://public.viavid.com/index.php?id=128299

About Spring Bank Pharmaceuticals
Spring Bank Pharmaceuticals is a clinical-stage biopharmaceutical company engaged in the discovery and development of a novel class of therapeutics using its proprietary small molecule nucleic acid hybrid (SMNH) chemistry platform. SMNH compounds are small segments of nucleic acids that the company designs to selectively target and modulate the activity of specific proteins implicated in various disease states. The company is developing its most advanced SMNH product candidate, inarigivir soproxil (formerly SB 9200) for the treatment of viral diseases, including hepatitis B virus (HBV). Spring Bank Pharmaceuticals is also developing other SMNH product candidates, including SB 11285, the company’s lead immunotherapeutic agent for the treatment of selected cancers through the activation of the STimulator of INterferon Genes, or STING, pathway. For more information, please visit www.springbankpharm.com


For investor inquires:
Spring Bank Pharmaceuticals, Inc.
Jonathan Freve
Chief Financial Officer
(508) 473-5993

LifeSci Advisors, LLC
Andrew McDonald, Ph.D.
(646) 597-6987

Media contact:
LifeSci Public Relations
Michael Tattory
(646) 751-4362

Source: Spring Bank Pharmaceuticals

Source:Spring Bank Pharmaceuticals, Inc.

More From Press Releases